Trials Offered by a Specific Doctor

Ana Tergas, MD
(212) 305-3410

Dr. Ana I. Tergas joined the faculty at Columbia University Medical Cancer New-York Presbyterian Hospital after completing a fellowship in Gynecologic Oncology at Johns Hopkins Medical Institutions in Baltimore, and residency in Obstetrics and Gynecology at the University of Chicago Hospitals in Chicago. Dr. Tergas cares for women with all gynecologic cancers, including cervical, endometrial, ovarian, vulvar, and vaginal cancers. In addition, she sees women with precancerous conditions of the lower genital tract, such as cervical and vulvar dysplasia, as well as endometrial hyperplasia.

Dr. Tergas has extensive training in minimally invasive laparoscopic surgery and in radical cytoreductive surgery for advanced cancers. She also performs risk-reducing surgeries for women with hereditary cancer syndromes. Dr. Tergas is actively involved in research in the United States and internationally and has expertise in epidemiology. Her primary research interests include public health issues in gynecologic cancers, particularly improving the quality of gynecologic cancer care for underserved and disadvantaged women. She has worked extensively in international cervical cancer prevention. She is also is actively involved with the division's survivorship program, and is working on study exploring sexual function in cancer survivors. She has authored over a dozen articles and textbook chapters, and she presents and lectures regularly at national and international conferences. Dr. Tergas is an active member of the Society of Gynecologic Oncology (SGO), International Gynecologic Cancer Society and American Society of Clinical Oncology. She serves on the SGO Quality and Outcomes Committee and on the CUMC Department of Obstetrics and Gynecology Quality and Patient Safety Committee.

Clinical Studies Managed By Dr. Tergas:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for women with cervical cancer using study drugs VGX-3100 and INO-9012InovioAAAO4206
Details[CLOSED] A study for women with ovarian cancer using study drug lurbinectedinPharmaMarAAAP3600
Details[CLOSED] Study of VGX-3100 for patients with squamous intraepithelial lesion (HSIL) of the vulvaInovio Pharmaceuticals, Inc.AAAR4755
Details[CLOSED] Study: Drug and Device Combination for Treatment HPV16 and/or HPV18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of CervixInovio Pharmaceuticals, Inc.AAAR3081
DetailsStudy of HVP16 and HPV18 Vaccine Components in Overwise Healthy Women with Persistent HPV16 or 18 Infection of the CervixJanssen Vaccines & Prevention B.V.AAAS0305
DetailsVGX-3100 Followed by Electroporation with Cellectra for HPV-related High-Grade Squamous Intraepithelial Lesion of Cervix (REVEAL 2)Inovio PharmaceuticalsAAAS2854
DetailsStudy of Durvalumab Following Chemoradiotherapy in Women with Locally Advanced Cervical CancerAstraZeneca ABAAAS3988